Skip to main content
OpenTrials
Completed

NCT Number: NCT01177657

Study to Evaluate the Effectiveness of Rotarix™ Against Severe Gastroenteritis Among Hospitalized Children in Brazil

The purpose of this study is to estimate the effectiveness of 2 doses of Rotarix™ vaccination in preventing rotavirus severe gastroenteritis among children hospitalized in Belem area, Brazil.

Completed

Looking for future studies?

Notify Me

Key information

Age range

12 week and older

Sex eligibility

All sexes

Study type

Observational

Primary location

GSK Investigational Site

Belém, Pará, 66 090 000, Brazil

About this study

The study will be comprised of two parts: Case-control study and Rotavirus strain surveillance.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

For cases:

  • A male or female child born after 6 March 2006 and at least 12 weeks of age.
  • Subject admitted to the study clinics/hospitals for severe gastroenteritis during the study period.
  • Onset of severe gastroenteritis ≤ 14 days prior to admission.
  • Laboratory confirmed rotavirus positive stool sample at hospital admission or during the first 48 hours of hospitalization.
  • Written informed consent obtained from the parent or guardian of the subject.

For controls:

  • Admitted for non-gastroenteritis causes at the same clinic/hospital as the case.
  • Living in the same neighbourhood as the case for at least three consecutive months without any symptoms of gastroenteritis or severe gastroenteritis on the day of interview of his/ her parents/ guardians.
  • Being born within +- 2 weeks from the date of birth of the case. If the number required is not available, then the range would be extended to +- 4 weeks, and ultimately up to +- 6 weeks for hospital controls. For neighbourhood controls, the range may be extended to +- 8 weeks.
  • Written informed consent obtained from the parent or guardian of the child.

Exclusion criteria

For cases:

  • Subject has previously participated as case or control in this study.
  • Onset of severe gastroenteritis > 48 hours after admission to the hospital (nosocomial infections).

For controls:

  • For hospital controls: Child who has symptoms of gastroenteritis during current hospitalization or on the day of interview of his/her parent or guardian or for neighbourhood controls: Child who has symptoms of gastroenteritis or severe gastroenteritis on the day of interview of his/her parent or guardian.
  • Exclude children with the following vaccine preventable diseases: measles, mumps, rubella, diphtheria, pertussis, tetanus, tuberculosis, invasive Haemophilus influenzae type B (Hib) infections (meningitis, bacteraemia, septic arthritis, cellulitis, and epiglottitis) and hepatitis B.
  • Child has participated in the past as a case or control in this study.
  • Child living in the same house as the case

Treatment and study plan

stool sampling

Procedure

Stool samples collected and checked for the presence of rotavirus

Primary outcomes

  1. Risk of Enzyme Linked Immunosorbent Assay (ELISA) confirmed rotavirus severe gastroenteritis in children fully vaccinated with Rotarix™, compared to risk of ELISA confirmed rotavirus severe gastroenteritis in unvaccinated children

    Time frame: Average time frame: 12-24 months

Secondary outcomes

  1. Risk of ELISA confirmed rotavirus severe gastroenteritis in children vaccinated with at least one dose of Rotarix™, compared to risk of ELISA confirmed rotavirus severe gastroenteritis in unvaccinated children

    Time frame: Average time frame: 12-24 months

  2. Occurrence of severe gastroenteritis among children admitted to study clinics/hospitals for severe gastroenteritis

    Time frame: Average time frame: 12-24 months

  3. Occurrence of rotavirus serotypes among children

    Time frame: Average time frame: 36 months

Sponsors and collaborators

Lead sponsor

GlaxoSmithKline

Industry

Registry information

Official study title

Case-control Study to Evaluate the Vaccine Effectiveness of Rotarix™ Against Rotavirus Severe Gastroenteritis (RV SGE) Among Hospitalized Children Born After 6 March 2006 and at Least 12 Weeks of Age, in Belem, Brazil

Important dates

Study start
2008
Primary completion
2011
Study completion
2011
First posted
Aug 9, 2010
Registry last updated
Nov 19, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.